Is Jagsonpal Pharma overvalued or undervalued?

As of June 5, 2024, Jagsonpal Pharma is considered very expensive and overvalued with a PE ratio of 39.87, significantly higher than its peers, indicating that investors may be paying too much for its future growth potential despite a strong recent performance.

As of 5 June 2024, Jagsonpal Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 39.87, a Price to Book Value of 6.45, and an EV to EBITDA of 27.96, all of which are elevated compared to industry norms.<BR><BR>In comparison to peers, Jagsonpal Pharma's PE ratio is higher than Sun Pharma's 35.25 and significantly exceeds Cipla's 22.99, highlighting its premium valuation. While the company has shown strong returns over the past year, with a 71.87% increase compared to the Sensex's 7.58%, the current valuation metrics suggest that investors may be paying too much for future growth potential.

Who are the top shareholders of the Jagsonpal Pharma?

The top shareholders of Jagsonpal Pharma include Aresko Progressive Private Limited with 20.08%, followed by individual investors holding 20.94%, and Manish Gupta as the highest public shareholder at 2.49%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Jagsonpal Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Aresko Progressive Private Limited, which owns 20.08% of the company. Additionally, there are 11 Foreign Institutional Investors (FIIs) holding a combined 2.1% of the shares. The highest public shareholder is Manish Gupta, with a holding of 2.49%. Individual investors collectively hold 20.94% of the shares. There are no pledged promoter holdings, and no mutual funds are currently invested in the company.

What does Jagsonpal Pharma do?

Jagsonpal Pharmaceuticals Ltd, established in 1978, manufactures and markets bulk drugs and pharmaceuticals, reporting net sales of ₹59 Cr and a net profit of ₹7 Cr for March 2025. The company has a market cap of ₹1,548 Cr and key metrics include a P/E ratio of 40.00 and a dividend yield of 0.86%.

Overview: <BR>Jagsonpal Pharmaceuticals Ltd is engaged in the manufacture and marketing of bulk drugs and pharmaceuticals, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap company.<BR><BR>History: <BR>Incorporated in August 1978, Jagsonpal Pharmaceuticals has maintained its status as a manufacturer and marketer of pharmaceuticals. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 59 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 7 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 1,548 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.86% <BR>Debt-Equity: -0.50 <BR>Return on Equity: 16.17% <BR>Price to Book: 6.44<BR><BR>Contact Details: <BR>Address: T-210 J, Shahpur Jat New Delhi New Delhi : 110049 <BR>Tel: 91-011-46181100/46109900 <BR>Email: nandita.singh@jagsonpal.com <BR>Website: http://www.jagsonpal.com

Has Jagsonpal Pharma declared dividend?

Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend, amounting to ₹5 per share, with an ex-date of September 6, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite a recent short-term decline.

Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 5<BR>- Ex-date: 06 Sep 24<BR><BR>Dividend Yield: 0.86%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.44%, with a dividend return of 0%, resulting in a total return of -15.44%.<BR><BR>Over the past year, the price return was 78.07%, the dividend return was 3.72%, leading to a total return of 81.79%.<BR><BR>In the last 2 years, the price return stood at 57.23%, with a dividend return of 3.24%, culminating in a total return of 60.47%.<BR><BR>For the 3-year period, the price return was 93.26%, the dividend return was 4.31%, resulting in a total return of 97.57%.<BR><BR>Over the past 4 years, the price return reached 361.1%, with a dividend return of 15.53%, leading to a total return of 376.63%.<BR><BR>In the 5-year period, the price return was an impressive 1943.42%, with a dividend return of 67.57%, resulting in a total return of 2010.99%.<BR><BR>Overall, Jagsonpal Pharmaceuticals Ltd has declared a significant dividend while demonstrating strong total returns over various periods, particularly notable in the longer-term performance. The company appears to be a solid investment with a consistent track record of returns, despite a recent decline in the short term.

Who are the peers of the Jagsonpal Pharma?

Jagsonpal Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Hester Bios, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma, and Remus Pharma. In terms of performance, Jagsonpal Pharma has a 1-year return of 78.37%, while its peers show varying management risks, growth rates, and capital structures.

Peers: The peers of Jagsonpal Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Hester Bios, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Jagsonpal Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma, and Remus Pharma. For growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted at Jagsonpal Pharma, and Below Average growth is present at Divi's Lab., Torrent Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma, and Remus Pharma. In terms of Capital Structure, Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Lincoln Pharma, while Good capital structure is found at Torrent Pharma and Average capital structure is observed at Jagsonpal Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, and Remus Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Themis Medicare at -33.90%. Jagsonpal Pharma's own 1-year return is 78.37%, which is significantly higher than both of these peers. Additionally, Hester Bios, Themis Medicare, and Lincoln Pharma have negative six-month returns.

Who are in the management team of Jagsonpal Pharma?

As of March 2023, the management team of Jagsonpal Pharma includes Manish Gupta (Managing Director), Harsha Raghavan (Chairman & Non-Executive Director), and several Independent and Non-Executive Directors, along with Abhishek Joshi (Company Secretary & Compliance Officer). Each member contributes to the company's governance and strategic direction.

As of March 2023, the management team of Jagsonpal Pharma includes the following individuals:<BR><BR>1. Manish Gupta - Managing Director<BR>2. Harsha Raghavan - Chairman & Non Executive Director<BR>3. Debasis Bikash Nandy - Independent Director<BR>4. Radhika Dudhat - Independent Director<BR>5. Pallavi Dinodia - Independent Director<BR>6. Prithipal Singh Kochhar - Non Executive Director<BR>7. Abhishek Joshi - Company Secretary & Compliance Officer<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

How big is Jagsonpal Pharma?

As of 24th July, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,762.00 Cr, with recent net sales of 268.72 Cr and a net profit of 55.36 Cr.

As of 24th July, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,762.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 268.72 Cr and a Net Profit of 55.36 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 187.40 Cr and Total Assets of 217.08 Cr.

When is the next results date for Jagsonpal Pharma?

Jagsonpal Pharma will announce its results on 03 November 2025.

Jagsonpal Pharma will declare its results on 03 November 2025.

Should I buy, sell or hold Jagsonpal Pharma?

How has been the historical performance of Jagsonpal Pharma?

Jagsonpal Pharma has shown significant financial growth, with net sales increasing from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, and profit after tax rising from 7.22 crore to 55.36 crore during the same period. The company has also improved its operating profit margin from 5.38% to 19.0%.

Answer:<BR>The historical performance of Jagsonpal Pharma shows a significant growth trajectory in its financial metrics over the years.<BR><BR>Breakdown:<BR>Jagsonpal Pharma's net sales increased from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 166.83 crore in Mar'19 to 268.72 crore in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 11.06 crore in Mar'20 to 59.26 crore in Mar'25, with an operating profit margin that improved from 5.38% to 19.0% during the same period. Profit before tax surged from 9.00 crore in Mar'19 to 69.86 crore in Mar'25, while profit after tax rose from 7.22 crore to 55.36 crore, indicating a robust increase in profitability. The company's total assets grew from 146.95 crore in Mar'20 to 278.26 crore in Mar'25, with total liabilities also increasing from 146.95 crore to 278.26 crore. Cash flow from operating activities improved significantly, reaching 55.00 crore in Mar'25 compared to 11.00 crore in Mar'20. Overall, Jagsonpal Pharma has demonstrated strong financial growth and improved profitability over the years.

Are Jagsonpal Pharma latest results good or bad?

Jagsonpal Pharmaceuticals' latest Q2 FY26 results are strong, with a net profit of ₹10.80 crores (up 102.63% year-on-year) and revenue growth of 23.06%. Despite the positive performance, the stock's high valuation may require caution for potential investors.

Jagsonpal Pharmaceuticals' latest results for Q2 FY26 are quite strong, indicating positive performance overall. The company reported a net profit of ₹10.80 crores, which is a remarkable increase of 102.63% year-on-year. Revenue also saw significant growth, reaching ₹75.61 crores, up 23.06% from the same quarter last year and reflecting a sequential increase of 29.12% from the previous quarter.<BR><BR>Additionally, the operating margin improved to 18.79%, up from 16.67% in the prior year, showcasing better operational efficiency. The profit after tax (PAT) margin also reached 14.28%, the best in five quarters, indicating strong profitability metrics.<BR><BR>Overall, these results suggest that Jagsonpal Pharmaceuticals is experiencing robust growth and improving operational efficiency, making the latest financial performance good. However, it's important to note that the stock is currently trading at a high valuation, which may warrant caution for potential investors.

Is Jagsonpal Pharma technically bullish or bearish?

As of December 1, 2025, Jagsonpal Pharma's trend is mildly bearish due to bearish momentum indicated by the weekly MACD and KST, despite some mixed signals from Bollinger Bands and Dow Theory.

As of 1 December 2025, the technical trend for Jagsonpal Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the daily moving averages also reflect a mildly bearish outlook. The weekly Bollinger Bands suggest a mildly bearish trend, contrasting with the monthly Bollinger Bands which are bullish. The Dow Theory shows a mildly bullish signal on the weekly timeframe, but overall, the lack of strong bullish signals in the MACD and RSI, combined with the mixed indicators, supports the mildly bearish stance.

Why is Jagsonpal Pharma falling/rising?

As of 03-Dec, Jagsonpal Pharmaceuticals Ltd's stock price is declining to Rs 214.55, down 2.03%, following a trend reversal after three days of gains. The stock has underperformed significantly over the past year, with a 24.76% negative return, amid declining investor interest and high valuation metrics.

As of 03-Dec, Jagsonpal Pharmaceuticals Ltd's stock price is falling, currently at Rs 214.55, which reflects a decrease of Rs 4.45 or 2.03%. This decline follows a trend reversal after three consecutive days of gains. The stock has underperformed its sector by 2.02% today and reached an intraday low of Rs 213.65, indicating a significant drop of 2.44% during the trading session.<BR><BR>In terms of broader performance, the stock has shown a negative return of 24.76% over the past year, significantly underperforming the market, which has generated a return of 2.66% in the same period. Despite the company reporting positive results for the last six consecutive quarters, including a highest PBDIT of Rs 16.44 crore and an operating profit to net sales ratio of 22.08%, the stock's valuation appears high with a Price to Book Value of 5.7 and a Return on Equity (ROE) of 17. <BR><BR>Additionally, there has been a notable decline in investor participation, with delivery volume falling by 17.86% against the five-day average. This lack of interest from investors, particularly domestic mutual funds which hold 0% of the company, may indicate discomfort with the current price or the business outlook. Overall, these factors contribute to the stock's current downward trajectory.

Which are the latest news on Jagsonpal Pharma?